Filtros : "MEDICAMENTO" "Inglês" "FCF" Removidos: "Colômbia" "1949" "Reunião Científica Anual do Instituto Butantan" Limpar

Filtros



Refine with date range


  • Source: International Journal of Pharmaceutics. Unidade: FCF

    Subjects: MEDICAMENTO, NEOPLASIAS

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      SUEYOSHI, Sophia Mikiko Oliveira et al. Dendrimers as drug delivery systems for oncotherapy: current status of promising applications. International Journal of Pharmaceutics, v. 663, p. 1-33 art. 124573, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.ijpharm.2024.124573. Acesso em: 07 out. 2024.
    • APA

      Sueyoshi, S. M. O., Silva, J. V. da, Guizze, F., & Giarolla, J. (2024). Dendrimers as drug delivery systems for oncotherapy: current status of promising applications. International Journal of Pharmaceutics, 663, 1-33 art. 124573. doi:10.1016/j.ijpharm.2024.124573
    • NLM

      Sueyoshi SMO, Silva JV da, Guizze F, Giarolla J. Dendrimers as drug delivery systems for oncotherapy: current status of promising applications [Internet]. International Journal of Pharmaceutics. 2024 ; 663 1-33 art. 124573.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1016/j.ijpharm.2024.124573
    • Vancouver

      Sueyoshi SMO, Silva JV da, Guizze F, Giarolla J. Dendrimers as drug delivery systems for oncotherapy: current status of promising applications [Internet]. International Journal of Pharmaceutics. 2024 ; 663 1-33 art. 124573.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1016/j.ijpharm.2024.124573
  • Source: Fluids. Unidade: FCF

    Subjects: PECTINA, MEDICAMENTO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      SILVA, Pedro Brivaldo Viana da e FABI, João Paulo. Overview of pectin-derived Microparticles through microfluidic technology. Fluids, v. 9, p. 1-19 art. 184., 2024Tradução . . Disponível em: https://dx.doi.org/10.3390/fluids9080184. Acesso em: 07 out. 2024.
    • APA

      Silva, P. B. V. da, & Fabi, J. P. (2024). Overview of pectin-derived Microparticles through microfluidic technology. Fluids, 9, 1-19 art. 184. doi:10.3390/fluids9080184
    • NLM

      Silva PBV da, Fabi JP. Overview of pectin-derived Microparticles through microfluidic technology [Internet]. Fluids. 2024 ; 9 1-19 art. 184.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.3390/fluids9080184
    • Vancouver

      Silva PBV da, Fabi JP. Overview of pectin-derived Microparticles through microfluidic technology [Internet]. Fluids. 2024 ; 9 1-19 art. 184.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.3390/fluids9080184
  • Source: Journal of Drug Delivery Science and Technology. Unidade: FCF

    Subjects: DEPRESSÃO, MEDICAMENTO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      RICHTER, Luca Maurice et al. Assessing the utility of in silico tools in early drug development: The case of a pharmaceutically relevant formulation of the prodrug psilocybin. Journal of Drug Delivery Science and Technology, v. 92, p. 1-14, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.jddst.2023.105305. Acesso em: 07 out. 2024.
    • APA

      Richter, L. M., Al-Gousous, J., Araujo, G. L. B. de, Davies, N. M., & Löbenberg, R. (2024). Assessing the utility of in silico tools in early drug development: The case of a pharmaceutically relevant formulation of the prodrug psilocybin. Journal of Drug Delivery Science and Technology, 92, 1-14. doi:10.1016/j.jddst.2023.105305
    • NLM

      Richter LM, Al-Gousous J, Araujo GLB de, Davies NM, Löbenberg R. Assessing the utility of in silico tools in early drug development: The case of a pharmaceutically relevant formulation of the prodrug psilocybin [Internet]. Journal of Drug Delivery Science and Technology. 2024 ; 92 1-14.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1016/j.jddst.2023.105305
    • Vancouver

      Richter LM, Al-Gousous J, Araujo GLB de, Davies NM, Löbenberg R. Assessing the utility of in silico tools in early drug development: The case of a pharmaceutically relevant formulation of the prodrug psilocybin [Internet]. Journal of Drug Delivery Science and Technology. 2024 ; 92 1-14.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1016/j.jddst.2023.105305
  • Source: RSC Medicinal Chemistry. Unidades: FCFRP, ICB, FCF

    Subjects: NEOPLASIAS, MEDICAMENTO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      HASSANIE, Haifa et al. SETDB1 as a cancer target: challenges and perspectives in drug design. RSC Medicinal Chemistry, v. 15, n. 5, p. 1424-1451, 2024Tradução . . Disponível em: https://dx.doi.org/10.1039/D3MD00366C. Acesso em: 07 out. 2024.
    • APA

      Hassanie, H., Penteado, A. B., Almeida, L. C. de, Calil, R. L., Emery, F. da S., Costa-Lotufo, L. V., & Trossini, G. H. G. (2024). SETDB1 as a cancer target: challenges and perspectives in drug design. RSC Medicinal Chemistry, 15( 5), 1424-1451. doi:10.1039/D3MD00366C
    • NLM

      Hassanie H, Penteado AB, Almeida LC de, Calil RL, Emery F da S, Costa-Lotufo LV, Trossini GHG. SETDB1 as a cancer target: challenges and perspectives in drug design [Internet]. RSC Medicinal Chemistry. 2024 ; 15( 5): 1424-1451.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1039/D3MD00366C
    • Vancouver

      Hassanie H, Penteado AB, Almeida LC de, Calil RL, Emery F da S, Costa-Lotufo LV, Trossini GHG. SETDB1 as a cancer target: challenges and perspectives in drug design [Internet]. RSC Medicinal Chemistry. 2024 ; 15( 5): 1424-1451.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1039/D3MD00366C
  • Source: Journal of AOAC International. Unidade: FCF

    Assunto: MEDICAMENTO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      LOURENÇO, Felipe Rebello e SILVA, Ricardo Jorge Neves Bettencourt da. Simplified and detailed evaluations of the uncertainty of the measurement of microbiological contamination of Pharmaceutical Products. Journal of AOAC International, 2024Tradução . . Disponível em: https://dx.doi.org/10.1093/jaoacint/qsae044. Acesso em: 07 out. 2024.
    • APA

      Lourenço, F. R., & Silva, R. J. N. B. da. (2024). Simplified and detailed evaluations of the uncertainty of the measurement of microbiological contamination of Pharmaceutical Products. Journal of AOAC International. doi:10.1093/jaoacint/qsae044
    • NLM

      Lourenço FR, Silva RJNB da. Simplified and detailed evaluations of the uncertainty of the measurement of microbiological contamination of Pharmaceutical Products [Internet]. Journal of AOAC International. 2024 ;[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1093/jaoacint/qsae044
    • Vancouver

      Lourenço FR, Silva RJNB da. Simplified and detailed evaluations of the uncertainty of the measurement of microbiological contamination of Pharmaceutical Products [Internet]. Journal of AOAC International. 2024 ;[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1093/jaoacint/qsae044
  • Source: Scientific Reports. Unidade: FCF

    Subjects: SAÚDE PÚBLICA, MEDICAMENTO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      OLIVEIRA, Stefane Cristina Paixão et al. Evaluation of drug litigation against the Campinas municipal health system from 2017 to 2021. Scientific Reports, v. 14, p. 1-11 art. 18764, 2024Tradução . . Disponível em: https://dx.doi.org/10.1038/s41598-024-68988-2. Acesso em: 07 out. 2024.
    • APA

      Oliveira, S. C. P., Moriel, P., Bonafé, M., & Visacri, M. B. (2024). Evaluation of drug litigation against the Campinas municipal health system from 2017 to 2021. Scientific Reports, 14, 1-11 art. 18764. doi:10.1038/s41598-024-68988-2
    • NLM

      Oliveira SCP, Moriel P, Bonafé M, Visacri MB. Evaluation of drug litigation against the Campinas municipal health system from 2017 to 2021 [Internet]. Scientific Reports. 2024 ; 14 1-11 art. 18764.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1038/s41598-024-68988-2
    • Vancouver

      Oliveira SCP, Moriel P, Bonafé M, Visacri MB. Evaluation of drug litigation against the Campinas municipal health system from 2017 to 2021 [Internet]. Scientific Reports. 2024 ; 14 1-11 art. 18764.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1038/s41598-024-68988-2
  • Source: Exploratory Research in Clinical and Social Pharmacy. Unidade: FCF

    Subjects: SERVIÇOS FARMACÊUTICOS, MEDICAMENTO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      SOUZA, Julie Faria Ferreira de et al. Key performance indicators for pharmaceutical services: a systematic review. Exploratory Research in Clinical and Social Pharmacy, v. 14, p. 1-8, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.rcsop.2024.100441. Acesso em: 07 out. 2024.
    • APA

      Souza, J. F. F. de, Fernandes, B. D., Rotta, I., Visacri, M. B., & Lima, T. de M. (2024). Key performance indicators for pharmaceutical services: a systematic review. Exploratory Research in Clinical and Social Pharmacy, 14, 1-8. doi:10.1016/j.rcsop.2024.100441
    • NLM

      Souza JFF de, Fernandes BD, Rotta I, Visacri MB, Lima T de M. Key performance indicators for pharmaceutical services: a systematic review [Internet]. Exploratory Research in Clinical and Social Pharmacy. 2024 ; 14 1-8.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1016/j.rcsop.2024.100441
    • Vancouver

      Souza JFF de, Fernandes BD, Rotta I, Visacri MB, Lima T de M. Key performance indicators for pharmaceutical services: a systematic review [Internet]. Exploratory Research in Clinical and Social Pharmacy. 2024 ; 14 1-8.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1016/j.rcsop.2024.100441
  • Source: Health Policy. Unidade: FCF

    Subjects: DOENÇAS RARAS, MEDICAMENTO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      FELIPPINI, Arturo et al. HTA criteria adopted in different models of public healthcare systems for orphan drugs: a scoping review. Health Policy, v. 144, p. 1-8 art. 105080, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.healthpol.2024.105080. Acesso em: 07 out. 2024.
    • APA

      Felippini, A., Biglia, L. V., Lima, T. de M., & Aguiar, P. M. (2024). HTA criteria adopted in different models of public healthcare systems for orphan drugs: a scoping review. Health Policy, 144, 1-8 art. 105080. doi:10.1016/j.healthpol.2024.105080
    • NLM

      Felippini A, Biglia LV, Lima T de M, Aguiar PM. HTA criteria adopted in different models of public healthcare systems for orphan drugs: a scoping review [Internet]. Health Policy. 2024 ; 144 1-8 art. 105080.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1016/j.healthpol.2024.105080
    • Vancouver

      Felippini A, Biglia LV, Lima T de M, Aguiar PM. HTA criteria adopted in different models of public healthcare systems for orphan drugs: a scoping review [Internet]. Health Policy. 2024 ; 144 1-8 art. 105080.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1016/j.healthpol.2024.105080
  • Source: Anais. Conference titles: Reunião Anual da Sociedade Brasileira de Química - RASBQ. Unidade: FCF

    Subjects: LEISHMANIA, MEDICAMENTO

    Acesso à fonteHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      PENTEADO, André Berndt e TROSSINI, Gustavo Henrique Goulart. Molecular modeling and structural comparison of leishmania sirtuin 2 enzymes, an epigenetic target in drug discovery. 2024, Anais.. São Paulo: Sociedade Brasileira de Química - SBQ, 2024. Disponível em: https://www.eventweb.com.br/rasbq2024/home-event/schedule.php?q=&area=todas&sessao=todas&tipo=1#trabalhos. Acesso em: 07 out. 2024.
    • APA

      Penteado, A. B., & Trossini, G. H. G. (2024). Molecular modeling and structural comparison of leishmania sirtuin 2 enzymes, an epigenetic target in drug discovery. In Anais. São Paulo: Sociedade Brasileira de Química - SBQ. Recuperado de https://www.eventweb.com.br/rasbq2024/home-event/schedule.php?q=&area=todas&sessao=todas&tipo=1#trabalhos
    • NLM

      Penteado AB, Trossini GHG. Molecular modeling and structural comparison of leishmania sirtuin 2 enzymes, an epigenetic target in drug discovery [Internet]. Anais. 2024 ;[citado 2024 out. 07 ] Available from: https://www.eventweb.com.br/rasbq2024/home-event/schedule.php?q=&area=todas&sessao=todas&tipo=1#trabalhos
    • Vancouver

      Penteado AB, Trossini GHG. Molecular modeling and structural comparison of leishmania sirtuin 2 enzymes, an epigenetic target in drug discovery [Internet]. Anais. 2024 ;[citado 2024 out. 07 ] Available from: https://www.eventweb.com.br/rasbq2024/home-event/schedule.php?q=&area=todas&sessao=todas&tipo=1#trabalhos
  • Source: Journal of Pharmaceutical and Biomedical Analysis. Unidade: FCF

    Subjects: MEDICAMENTO, MÉTODO DE MONTE CARLO, MEDIÇÃO DE RISCO

    PrivadoAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      MARTINS, Maisa Torres e LOURENÇO, Felipe Rebello. Measurement uncertainty for < 905 > Uniformity of Dosage Units tests using Monte Carlo and bootstrapping methods – Uncertainties arising from sampling and analytical steps. Journal of Pharmaceutical and Biomedical Analysis, v. 238, p. 1-8 art. 115857, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.jpba.2023.115857. Acesso em: 07 out. 2024.
    • APA

      Martins, M. T., & Lourenço, F. R. (2024). Measurement uncertainty for < 905 > Uniformity of Dosage Units tests using Monte Carlo and bootstrapping methods – Uncertainties arising from sampling and analytical steps. Journal of Pharmaceutical and Biomedical Analysis, 238, 1-8 art. 115857. doi:10.1016/j.jpba.2023.115857
    • NLM

      Martins MT, Lourenço FR. Measurement uncertainty for < 905 > Uniformity of Dosage Units tests using Monte Carlo and bootstrapping methods – Uncertainties arising from sampling and analytical steps [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2024 ; 238 1-8 art. 115857.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1016/j.jpba.2023.115857
    • Vancouver

      Martins MT, Lourenço FR. Measurement uncertainty for < 905 > Uniformity of Dosage Units tests using Monte Carlo and bootstrapping methods – Uncertainties arising from sampling and analytical steps [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2024 ; 238 1-8 art. 115857.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1016/j.jpba.2023.115857
  • Source: Microchemical Journal. Unidade: FCF

    Subjects: CROMATOGRAFIA LÍQUIDA DE ALTA EFICIÊNCIA, MEDICAMENTO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      LOPES, Ivone de Jesus do Nascimento et al. Application of analytical quality by design (AQbD) for stability-indicating method development for quantification of nevirapine and its degradation products. Microchemical Journal, v. 199, p. 1-9 art. 109939, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.microc.2024.109939. Acesso em: 07 out. 2024.
    • APA

      Lopes, I. de J. do N., Fujimori, S. K., Mendes, T. de C., Almeida, R. A. D. de, Sousa, F. F. de M. de, Oliveira, C. A. de, et al. (2024). Application of analytical quality by design (AQbD) for stability-indicating method development for quantification of nevirapine and its degradation products. Microchemical Journal, 199, 1-9 art. 109939. doi:10.1016/j.microc.2024.109939
    • NLM

      Lopes I de J do N, Fujimori SK, Mendes T de C, Almeida RAD de, Sousa FF de M de, Oliveira CA de, Nascimento DD do, Lourenço FR, Rodrigues MI, Prado LD. Application of analytical quality by design (AQbD) for stability-indicating method development for quantification of nevirapine and its degradation products [Internet]. Microchemical Journal. 2024 ; 199 1-9 art. 109939.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1016/j.microc.2024.109939
    • Vancouver

      Lopes I de J do N, Fujimori SK, Mendes T de C, Almeida RAD de, Sousa FF de M de, Oliveira CA de, Nascimento DD do, Lourenço FR, Rodrigues MI, Prado LD. Application of analytical quality by design (AQbD) for stability-indicating method development for quantification of nevirapine and its degradation products [Internet]. Microchemical Journal. 2024 ; 199 1-9 art. 109939.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1016/j.microc.2024.109939
  • Source: Preparative Biochemistry & Biotechnology. Unidade: FCF

    Subjects: TERMODINÂMICA, MEDICAMENTO

    PrivadoAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      OBREQUE, Karin Mariana Torres et al. PEGylation versus glycosylation: effect on the thermodynamics and thermostability of crisantaspase. Preparative Biochemistry & Biotechnology, v. 54, n. 4, p. 503-513, 2024Tradução . . Disponível em: https://doi.org/10.1080/10826068.2023.2249100. Acesso em: 07 out. 2024.
    • APA

      Obreque, K. M. T., Kleingesinds, E. K., Santos, J. H. P. M., Carretero, G. P. B., Cunha, J. R., Converti, A., et al. (2024). PEGylation versus glycosylation: effect on the thermodynamics and thermostability of crisantaspase. Preparative Biochemistry & Biotechnology, 54( 4), 503-513. doi:10.1080/10826068.2023.2249100
    • NLM

      Obreque KMT, Kleingesinds EK, Santos JHPM, Carretero GPB, Cunha JR, Converti A, Monteiro G, Pessoa Junior A, Rangel-Yagui C de O. PEGylation versus glycosylation: effect on the thermodynamics and thermostability of crisantaspase [Internet]. Preparative Biochemistry & Biotechnology. 2024 ; 54( 4): 503-513.[citado 2024 out. 07 ] Available from: https://doi.org/10.1080/10826068.2023.2249100
    • Vancouver

      Obreque KMT, Kleingesinds EK, Santos JHPM, Carretero GPB, Cunha JR, Converti A, Monteiro G, Pessoa Junior A, Rangel-Yagui C de O. PEGylation versus glycosylation: effect on the thermodynamics and thermostability of crisantaspase [Internet]. Preparative Biochemistry & Biotechnology. 2024 ; 54( 4): 503-513.[citado 2024 out. 07 ] Available from: https://doi.org/10.1080/10826068.2023.2249100
  • Source: Expert Opinion on Therapeutic Targets. Unidade: FCF

    Subjects: DOENÇA DE CHAGAS, MEDICAMENTO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      SOUZA, Mariana Laureano de et al. Molecular targets for Chagas disease: validation, challenges and lead compounds for widely exploited targets. Expert Opinion on Therapeutic Targets, v. 27, p. 911-925, 2023Tradução . . Disponível em: https://dx.doi.org/10.1080/14728222.2023.2264512. Acesso em: 07 out. 2024.
    • APA

      Souza, M. L. de, Lapierre, thibault J. W. J. D., Marques, G. V. de L., Ferraz, W. R., Penteado, A. B., Trossini, G. H. G., et al. (2023). Molecular targets for Chagas disease: validation, challenges and lead compounds for widely exploited targets. Expert Opinion on Therapeutic Targets, 27, 911-925. doi:10.1080/14728222.2023.2264512
    • NLM

      Souza ML de, Lapierre thibault JWJD, Marques GV de L, Ferraz WR, Penteado AB, Trossini GHG, Murta SMF, Oliveira RB de, Rezende Junior C de O, Ferreira RS. Molecular targets for Chagas disease: validation, challenges and lead compounds for widely exploited targets [Internet]. Expert Opinion on Therapeutic Targets. 2023 ; 27 911-925.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1080/14728222.2023.2264512
    • Vancouver

      Souza ML de, Lapierre thibault JWJD, Marques GV de L, Ferraz WR, Penteado AB, Trossini GHG, Murta SMF, Oliveira RB de, Rezende Junior C de O, Ferreira RS. Molecular targets for Chagas disease: validation, challenges and lead compounds for widely exploited targets [Internet]. Expert Opinion on Therapeutic Targets. 2023 ; 27 911-925.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1080/14728222.2023.2264512
  • Source: Chemometrics and Intelligent Laboratory Systems. Unidade: FCF

    Subjects: ENDOTOXINAS, MEDICAMENTO

    PrivadoAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      COUTO, Aldo Renato e PASSARIN, Paula Beatriz Silva e LOURENÇO, Felipe Rebello. Risk of false conformity decisions in LAL gel-clot test due to false-negative results. Chemometrics and Intelligent Laboratory Systems, v. 234, p. 1-6 art. 104760, 2023Tradução . . Disponível em: https://doi.org/10.1016/j.chemolab.2023.104760. Acesso em: 07 out. 2024.
    • APA

      Couto, A. R., Passarin, P. B. S., & Lourenço, F. R. (2023). Risk of false conformity decisions in LAL gel-clot test due to false-negative results. Chemometrics and Intelligent Laboratory Systems, 234, 1-6 art. 104760. doi:10.1016/j.chemolab.2023.104760
    • NLM

      Couto AR, Passarin PBS, Lourenço FR. Risk of false conformity decisions in LAL gel-clot test due to false-negative results [Internet]. Chemometrics and Intelligent Laboratory Systems. 2023 ; 234 1-6 art. 104760.[citado 2024 out. 07 ] Available from: https://doi.org/10.1016/j.chemolab.2023.104760
    • Vancouver

      Couto AR, Passarin PBS, Lourenço FR. Risk of false conformity decisions in LAL gel-clot test due to false-negative results [Internet]. Chemometrics and Intelligent Laboratory Systems. 2023 ; 234 1-6 art. 104760.[citado 2024 out. 07 ] Available from: https://doi.org/10.1016/j.chemolab.2023.104760
  • Source: International Journal of Pharmaceutics. Unidade: FCF

    Subjects: ENTEROPATIAS INFLAMATÓRIAS, MEDICAMENTO, BIOFARMACOLOGIA

    PrivadoAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      CACHUMBA, Jorge Javier Muso et al. Polymersomes for protein drug delivery across intestinal mucosa. International Journal of Pharmaceutics, v. 648, p. 1-9 art. 123613, 2023Tradução . . Disponível em: https://dx.doi.org/10.1016/j.ijpharm.2023.123613. Acesso em: 07 out. 2024.
    • APA

      Cachumba, J. J. M., Feng, S., Belaid, M., Zhang, Y., Rangel-Yagui, C. de O., & Vllasaliu, D. (2023). Polymersomes for protein drug delivery across intestinal mucosa. International Journal of Pharmaceutics, 648, 1-9 art. 123613. doi:10.1016/j.ijpharm.2023.123613
    • NLM

      Cachumba JJM, Feng S, Belaid M, Zhang Y, Rangel-Yagui C de O, Vllasaliu D. Polymersomes for protein drug delivery across intestinal mucosa [Internet]. International Journal of Pharmaceutics. 2023 ; 648 1-9 art. 123613.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1016/j.ijpharm.2023.123613
    • Vancouver

      Cachumba JJM, Feng S, Belaid M, Zhang Y, Rangel-Yagui C de O, Vllasaliu D. Polymersomes for protein drug delivery across intestinal mucosa [Internet]. International Journal of Pharmaceutics. 2023 ; 648 1-9 art. 123613.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1016/j.ijpharm.2023.123613
  • Source: Research in Pharmaceutical Sciences. Unidade: FCF

    Subjects: LISOSSOMOS, MEDICAMENTO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      YOUSEF, Malaz et al. Sub-cellular sequestration of alkaline drugs in lysosomes: new insights for pharmaceutical development of lysosomal fluid. Research in Pharmaceutical Sciences, v. 18, n. 1, p. 1-15, 2023Tradução . . Disponível em: https://doi.org/10.4103/1735-5362.363591. Acesso em: 07 out. 2024.
    • APA

      Yousef, M., Le, T. S., Zuo, J., Park, C., Bou-Chacra, N. A., Davies, N. M., & Löbenberg, R. (2023). Sub-cellular sequestration of alkaline drugs in lysosomes: new insights for pharmaceutical development of lysosomal fluid. Research in Pharmaceutical Sciences, 18( 1), 1-15. doi:10.4103/1735-5362.363591
    • NLM

      Yousef M, Le TS, Zuo J, Park C, Bou-Chacra NA, Davies NM, Löbenberg R. Sub-cellular sequestration of alkaline drugs in lysosomes: new insights for pharmaceutical development of lysosomal fluid [Internet]. Research in Pharmaceutical Sciences. 2023 ; 18( 1): 1-15.[citado 2024 out. 07 ] Available from: https://doi.org/10.4103/1735-5362.363591
    • Vancouver

      Yousef M, Le TS, Zuo J, Park C, Bou-Chacra NA, Davies NM, Löbenberg R. Sub-cellular sequestration of alkaline drugs in lysosomes: new insights for pharmaceutical development of lysosomal fluid [Internet]. Research in Pharmaceutical Sciences. 2023 ; 18( 1): 1-15.[citado 2024 out. 07 ] Available from: https://doi.org/10.4103/1735-5362.363591
  • Source: SAR and QSAR in Environmental Research. Unidade: FCF

    Subjects: LEISHMANIA, MEDICAMENTO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      SILVA, J.V et al. Pteridine reductase (PTR1): initial structureactivity relationships studies of potential leishmanicidal arylindole derivatives compounds. SAR and QSAR in Environmental Research, v. 34, n. 8, p. 661–687, 2023Tradução . . Disponível em: https://dx.doi.org/10.1080/1062936X.2023.2247331. Acesso em: 07 out. 2024.
    • APA

      Silva, J. V., Sueyoshia, S., Snape, T. J., Lal, S., & Giarolla, J. (2023). Pteridine reductase (PTR1): initial structureactivity relationships studies of potential leishmanicidal arylindole derivatives compounds. SAR and QSAR in Environmental Research, 34( 8), 661–687. doi:10.1080/1062936X.2023.2247331
    • NLM

      Silva JV, Sueyoshia S, Snape TJ, Lal S, Giarolla J. Pteridine reductase (PTR1): initial structureactivity relationships studies of potential leishmanicidal arylindole derivatives compounds [Internet]. SAR and QSAR in Environmental Research. 2023 ; 34( 8): 661–687.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1080/1062936X.2023.2247331
    • Vancouver

      Silva JV, Sueyoshia S, Snape TJ, Lal S, Giarolla J. Pteridine reductase (PTR1): initial structureactivity relationships studies of potential leishmanicidal arylindole derivatives compounds [Internet]. SAR and QSAR in Environmental Research. 2023 ; 34( 8): 661–687.[citado 2024 out. 07 ] Available from: https://dx.doi.org/10.1080/1062936X.2023.2247331
  • Source: Current Topics in Medicinal Chemistry. Unidade: FCF

    Subjects: MEDICAMENTO, METABOLISMO

    PrivadoAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      CUPPOLONI, Andréa et al. 2,3-Diarylindoles as COX-2 Inhibitors: exploring the structure-activity relationship through molecular docking simulations. Current Topics in Medicinal Chemistry, v. 23, n. 12, p. 1081-1089, 2023Tradução . . Disponível em: https://doi.org/10.2174/1568026623666230207120752. Acesso em: 07 out. 2024.
    • APA

      Cuppoloni, A., Silva, J. V. da, Snape, T. J., Lal, S., & Giarolla, J. (2023). 2,3-Diarylindoles as COX-2 Inhibitors: exploring the structure-activity relationship through molecular docking simulations. Current Topics in Medicinal Chemistry, 23( 12), 1081-1089. doi:10.2174/1568026623666230207120752
    • NLM

      Cuppoloni A, Silva JV da, Snape TJ, Lal S, Giarolla J. 2,3-Diarylindoles as COX-2 Inhibitors: exploring the structure-activity relationship through molecular docking simulations [Internet]. Current Topics in Medicinal Chemistry. 2023 ; 23( 12): 1081-1089.[citado 2024 out. 07 ] Available from: https://doi.org/10.2174/1568026623666230207120752
    • Vancouver

      Cuppoloni A, Silva JV da, Snape TJ, Lal S, Giarolla J. 2,3-Diarylindoles as COX-2 Inhibitors: exploring the structure-activity relationship through molecular docking simulations [Internet]. Current Topics in Medicinal Chemistry. 2023 ; 23( 12): 1081-1089.[citado 2024 out. 07 ] Available from: https://doi.org/10.2174/1568026623666230207120752
  • Source: Brazilian Journal of Pharmaceutical Sciences. Unidade: FCF

    Subjects: MEDICAMENTO, FALSIFICAÇÃO

    Versão PublicadaAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      LIMA, Marcela Bittar Araujo e YONAMINE, Maurício. Counterfeit medicines: relevance, consequences and strategies to combat the global crisis. Brazilian Journal of Pharmaceutical Sciences, v. 59, p. 1-16 art. e20402, 2023Tradução . . Disponível em: https://doi.org/10.1590/s2175-97902023e20402. Acesso em: 07 out. 2024.
    • APA

      Lima, M. B. A., & Yonamine, M. (2023). Counterfeit medicines: relevance, consequences and strategies to combat the global crisis. Brazilian Journal of Pharmaceutical Sciences, 59, 1-16 art. e20402. doi:10.1590/s2175-97902023e20402
    • NLM

      Lima MBA, Yonamine M. Counterfeit medicines: relevance, consequences and strategies to combat the global crisis [Internet]. Brazilian Journal of Pharmaceutical Sciences. 2023 ; 59 1-16 art. e20402.[citado 2024 out. 07 ] Available from: https://doi.org/10.1590/s2175-97902023e20402
    • Vancouver

      Lima MBA, Yonamine M. Counterfeit medicines: relevance, consequences and strategies to combat the global crisis [Internet]. Brazilian Journal of Pharmaceutical Sciences. 2023 ; 59 1-16 art. e20402.[citado 2024 out. 07 ] Available from: https://doi.org/10.1590/s2175-97902023e20402
  • Source: Value in Health. Conference titles: ISPOR Europe. Unidade: FCF

    Subjects: DOENÇAS RARAS, MEDICAMENTO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      BIGLIA, Luiza Vasconcelos et al. Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil. Value in Health. Amsterdam: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.jval.2023.09.1783. Acesso em: 07 out. 2024. , 2023
    • APA

      Biglia, L. V., Felippini, A., Ribeiro, T. B., Lima, T. D. M., & Aguiar, P. M. (2023). Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil. Value in Health. Amsterdam: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. doi:10.1016/j.jval.2023.09.1783
    • NLM

      Biglia LV, Felippini A, Ribeiro TB, Lima TDM, Aguiar PM. Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil [Internet]. Value in Health. 2023 ; 26( 12): S337.[citado 2024 out. 07 ] Available from: https://doi.org/10.1016/j.jval.2023.09.1783
    • Vancouver

      Biglia LV, Felippini A, Ribeiro TB, Lima TDM, Aguiar PM. Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil [Internet]. Value in Health. 2023 ; 26( 12): S337.[citado 2024 out. 07 ] Available from: https://doi.org/10.1016/j.jval.2023.09.1783

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2024